Date: 2016-05-05
Type of information: Collaboration agreement
Compound: app for iPhone and iPad to assist surgeons who perform cataract surgery
Company: Valeant Pharmaceuticals (Canada) Bausch&Lomb (USA) IBM (USA)
Therapeutic area: Ophtalmological diseases
Type agreement: collaboration
Action mechanism:
Disease: Cataracts
Details: * On May 5, 2016, Valeant Pharmaceuticals wholly owned subsidiary, Bausch + Lomb, and IBM annouced a collaboration to develop an app for iPhone and iPad to assist surgeons who perform cataract surgery. The app will help surgeons streamline their workflow by delivering patient information and clinical insights as well as intraocular lens (IOL) selection guidance on a single digital platform at the point of care.
The app will be designed to electronically manage patient data across iPhone and iPad while hosting health-related data on IBM Cloud and relaying informed, customized IOL options to surgeons that they will use to help enhance surgical planning and provide better patient care. The MobileFirst for iOS team, which is part of IBM Global Business Services, will design and develop this custom app for Bausch + Lomb to help drive innovation in healthcare. Bausch + Lomb's vision is to optimize the app to collect data over time, resulting in a cognitive app that applies machine-based learning and predictive analytics to deliver real-times insights to surgeons. Pilot study testing for the new application is expected to begin in late 2016.
Financial terms:
Latest news:
